Print this page

Targeted Cancer Therapy


Nordic Nanovector AS is a privately held company based in Oslo, Norway. The company was established in 2009. Our mission is to develop innovative radioimmunotherapeutics that target difficult to treat cancers using the company’s proprietary nanovector targeting technology.

Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets.


 

March 28, 2014
Article in Finansavisen (Norwegian only)

See link for details.

March 27, 2014
Betalutin™ successful completion of phase I part of phase I/II study (Press Release 06/2014) See link for details.

March 27, 2014
Fourth Quarter and Full Year Report 2013
(Press Release 05/2014) See link for details.

 



 

 




Next page: About us